Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of tenofovir disoproxil
fumarate (tenofovir DF; TDF) plus a genotype-guided optimized background regimen (OBR)
compared to placebo plus OBR in the treatment of human immunodeficiency virus type 1 (HIV-1)
infected antiretroviral treatment-experienced adolescents with plasma HIV-1 ribonucleic acid
(RNA) levels greater than or equal to 1000 copies/mL.